Compare EPSN & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | BDSX |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Precision Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 122.0M |
| IPO Year | 2018 | 2020 |
| Metric | EPSN | BDSX |
|---|---|---|
| Price | $5.61 | $17.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 217.8K | 153.6K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | $41.35 | $23.35 |
| Revenue Next Year | N/A | $19.33 |
| P/E Ratio | $19.17 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $4.20 | $0.25 |
| 52 Week High | $8.50 | $20.21 |
| Indicator | EPSN | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 63.03 | 62.47 |
| Support Level | $5.33 | $6.33 |
| Resistance Level | $6.49 | N/A |
| Average True Range (ATR) | 0.20 | 1.84 |
| MACD | 0.04 | 0.20 |
| Stochastic Oscillator | 71.75 | 65.98 |
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.